A Study of Clinical Efficacy of Pitavastatin on Patients with Hypercholesterolemia-Including Evaluations of hs-CRP and Adipocytokines-
|
Accession number;06A0013915
|
| Title;A Study of Clinical Efficacy of Pitavastatin on Patients with Hypercholesterolemia-Including Evaluations of hs-CRP and Adipocytokines- |
| Author;
OBAYASHI HIROYUKI
(Jagifukoseiren Tonokoseibyoin Naika)
|
Journal Title;Journal of Clinical Therapeutics & Medicines
|
Journal Code:Y0906A
|
ISSN:0910-8211
|
|
VOL.21;NO.12;PAGE.1163-1170(2005)
|
| Figure&Table&Reference;FIG.1, TBL.2, REF.20 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Objective: The aim of this study was to examine whether pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has not only a potent serum lipid-lowering effect but also improvement effects on high-sensitivity C-reactive protein (hs-CRP) and adipocytokines in clinical practice. Method: Pitavastatin was administered at a dose of 2 mg/day to 47 patients (mean age 63.1.+-.12.1, male to female ratio 23:24) with hypercholesterolemia diagnosed according to criteria of the Japan Atherosclerosis Society GAS) Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases (version 2002), who had not received this drug previously. Biochemical values such as serum lipid, hs-CRP, adiponectin, leptin, and tumor necrosis factor-alfa (TNF-alfa) were determined, and their changes from baseline were evaluated for 12 weeks after pitavastatin administration. Results: Serum total cholesterol and LDL-cholesterol levels were significantly decreased at 4 weeks after administration compared to baseline (254.3.+-.37.8 mg/dL versus 191.7.+-.36.3 mg/dL (p<0.001) and 164.0.+-.37.7 mg/ dL versus 107.8.+-.34.5 mg/dL (p<0.001), respectively). Throughout the 12-week dosing period, no adipocytokines showed significant changes, however, TNF-alpha and leptin showed a tendency toward a decrease. As for hs-CRP, when the patients were divided into quartiles based on hs-CRP levels obtained before the administration, the mean level in the highest quartile group was significantly decreased from 0.388.+-.0.121 mg/dL at baseline to 0.178.+-.0.143 mg/dL at 4 weeks after administration (P<0.01). This significant decrease was also observed at 12 weeks after administration. These changes in hs-CRP levels showed no correlation with those in serum cholesterol levels. Throughout the 12-week dosing period, no influence of pitavastatin was observed on insulin resistance and biochemical determinations including liver function test values.... (author abst.) |
|
|
|
Related Articles;
|
|
